Key Takeaways
- Demeetra AgBio has completed and fully integrated its acquisition of Hera BioLabs as of June 1.
- The transaction consolidates commercial access to the hyperactive Super piggyBac® transposase platform under Demeetra.
- Demeetra is now the definitive commercial source for Super piggyBac licensing across multiple fields of use.
- The integration simplifies licensing pathways and improves freedom to operate for developers and researchers.
- Super piggyBac supports non-viral genome engineering across cell and gene therapy, research tools, and biomanufacturing.
Demeetra AgBio Finalizes Hera BioLabs Acquisition
Demeetra AgBio, a genome engineering company focused on enabling research and biomanufacturing through advanced gene-editing technologies and engineered CHO host cells, has announced the completion and full integration of its acquisition of Hera BioLabs. The transaction, completed on June 1, consolidates rights to the hyperactive Super piggyBac® transposase platform under Demeetra, establishing the company as the central commercial source for licensing and access.
According to Demeetra, the integration brings clarity to the intellectual property landscape surrounding Super piggyBac, addressing longstanding uncertainty related to licensing, downstream rights, and freedom-to-operate considerations.
Consolidating Access to the Super piggyBac Platform
Licensing Clarity and Performance Attributes
Super piggyBac is a proprietary, non-viral transposase platform developed through protein engineering and protected by U.S. and international patents and trademarks. The platform offers higher integration efficiency and increased transgene copy number compared with wild-type piggyBac, while maintaining large cargo capacity and a favorable genomic integration profile.
